dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 26, 2026

Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness

View original at finance.yahoo.com
Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Simply Wall St is trusted by over 7 million individual investors worldwide

    60% confidence

  • Analyst and extrapolated forecasts project Sanofi's free cash flow to reach €12.72 billion in 2030, with intermediate annual projections through 2035

    60% confidence

  • Sanofi currently has a value score of 6 out of 6

    60% confidence

  • Sanofi's -9.5% return over the last year is lagging behind its pharmaceutical sector peers

    60% confidence

  • There are 230 or more high quality undervalued stocks available to discover on Simply Wall St's platform

    60% confidence

  • Recent sentiment around Sanofi has been mixed due to broader pharmaceutical sector dynamics, regulatory developments, and shifting investor attention within healthcare

    60% confidence

  • Sanofi is undervalued by 68.7% according to a 2-Stage Free Cash Flow to Equity DCF model, with an estimated intrinsic value of €255.70 per share versus a current price of approximately €80.08

    60% confidence

Data points we hold from this source

Sanofi · margin-68.7 percent
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness: Source | Via News | fr.via.news